Balyasny Asset Management LLC Abb Vie Inc. Call Options Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $15.1 Million - $18.3 Million	91,900 Added 827.93%	103,000 $20.3 Million
Q2 2024 Aug 14, 2024	SELL	$154.79 - $180.76 $959,698 - $1.12 Million	-6,200 Reduced 35.84%	11,100 $1.9 Million
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $1.58 Million - $1.8 Million	-9,900 Reduced 36.4%	17,300 $3.15 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $1.03 Million - $1.16 Million	7,500 Added 38.07%	27,200 $4.22 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $2.63 Million - $3.05 Million	19,700 New	19,700 $2.94 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $5.97 Million - $6.85 Million	44,500 Added 296.67%	59,500 $7.99 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $1.14 Million - $1.45 Million	8,300 Added 123.88%	15,000 $2.3 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $7.71 Million - $8.59 Million	-73,300 Reduced 91.63%	6,700 $755,000
Q1 2020 May 15, 2020	SELL	$64.5 - $97.79 $14.2 Million - $21.5 Million	-220,200 Reduced 73.35%	80,000 $6.1 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $21 Million - $26.8 Million	300,200	300,200 $26.7 Million

3,849

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $321B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.